Aquaculture biotechnology group Benchmark moved a step closer to reaching the necessary approvals required to launch its new medicinal sea lice treatment, BMK08, after receiving a “positive opinion” from the European Medicine Agency on the product’s safety.
On Sept. 10, the Committee for Medicinal Products for Veterinary Use (CVMP) – which forms part of the European Medicine Agency -- adopted an opinion recommending the inclusion of BMK08's active pharmaceutical ingredient in fin fish as “an allowed substance regarding maximum residue limits (MRL) in foodstuffs of animal origin”.
